117 related articles for article (PubMed ID: 27125456)
1. Detection of O-propargyl-puromycin with SUMO and ubiquitin by click chemistry at PML-nuclear bodies during abortive proteasome activities.
Uozumi N; Matsumoto H; Saitoh H
Biochem Biophys Res Commun; 2016 May; 474(2):247-251. PubMed ID: 27125456
[TBL] [Abstract][Full Text] [Related]
2. Puromycin induces SUMO and ubiquitin redistribution upon proteasome inhibition.
Matsumoto H; Saitoh H
Biochem Biophys Res Commun; 2016 Jul; 476(3):153-8. PubMed ID: 27181354
[TBL] [Abstract][Full Text] [Related]
3. The PML-nuclear inclusion of human supraoptic neurons: a new compartment with SUMO-1- and ubiquitin-proteasome-associated domains.
Villagra NT; Navascues J; Casafont I; Val-Bernal JF; Lafarga M; Berciano MT
Neurobiol Dis; 2006 Jan; 21(1):181-93. PubMed ID: 16125395
[TBL] [Abstract][Full Text] [Related]
4. Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes.
Moran DM; Shen H; Maki CG
BMC Cell Biol; 2009 May; 10():32. PubMed ID: 19409099
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the SUMO1 and ubiquitin conjugation pathways during the inhibition of proteasome activity with evidence of SUMO1 recycling.
Bailey D; O'Hare P
Biochem J; 2005 Dec; 392(Pt 2):271-81. PubMed ID: 16117725
[TBL] [Abstract][Full Text] [Related]
6. Stabilization of PML nuclear localization by conjugation and oligomerization of SUMO-3.
Fu C; Ahmed K; Ding H; Ding X; Lan J; Yang Z; Miao Y; Zhu Y; Shi Y; Zhu J; Huang H; Yao X
Oncogene; 2005 Aug; 24(35):5401-13. PubMed ID: 15940266
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting ubiquitination causes an accumulation of SUMOylated newly synthesized nuclear proteins at PML bodies.
Sha Z; Blyszcz T; González-Prieto R; Vertegaal ACO; Goldberg AL
J Biol Chem; 2019 Oct; 294(42):15218-15234. PubMed ID: 31285264
[TBL] [Abstract][Full Text] [Related]
8. N4BP1 is a newly identified nucleolar protein that undergoes SUMO-regulated polyubiquitylation and proteasomal turnover at promyelocytic leukemia nuclear bodies.
Sharma P; Murillas R; Zhang H; Kuehn MR
J Cell Sci; 2010 Apr; 123(Pt 8):1227-34. PubMed ID: 20233849
[TBL] [Abstract][Full Text] [Related]
9. Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner.
Dubuisson L; Lormières F; Fochi S; Turpin J; Pasquier A; Douceron E; Oliva A; Bazarbachi A; Lallemand-Breitenbach V; De Thé H; Journo C; Mahieux R
Oncogene; 2018 May; 37(21):2806-2816. PubMed ID: 29507418
[TBL] [Abstract][Full Text] [Related]
10. RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.
Tatham MH; Geoffroy MC; Shen L; Plechanovova A; Hattersley N; Jaffray EG; Palvimo JJ; Hay RT
Nat Cell Biol; 2008 May; 10(5):538-46. PubMed ID: 18408734
[TBL] [Abstract][Full Text] [Related]
11. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.
Meinecke I; Cinski A; Baier A; Peters MA; Dankbar B; Wille A; Drynda A; Mendoza H; Gay RE; Hay RT; Ink B; Gay S; Pap T
Proc Natl Acad Sci U S A; 2007 Mar; 104(12):5073-8. PubMed ID: 17360386
[TBL] [Abstract][Full Text] [Related]
12. REGgamma/PA28gamma proteasome activator interacts with PML and Chk2 and affects PML nuclear bodies number.
Zannini L; Buscemi G; Fontanella E; Lisanti S; Delia D
Cell Cycle; 2009 Aug; 8(15):2399-407. PubMed ID: 19556897
[TBL] [Abstract][Full Text] [Related]
13. Cell-type-specific quantification of protein synthesis in vivo.
Hidalgo San Jose L; Signer RAJ
Nat Protoc; 2019 Feb; 14(2):441-460. PubMed ID: 30610239
[TBL] [Abstract][Full Text] [Related]
14. Dynamics of component exchange at PML nuclear bodies.
Weidtkamp-Peters S; Lenser T; Negorev D; Gerstner N; Hofmann TG; Schwanitz G; Hoischen C; Maul G; Dittrich P; Hemmerich P
J Cell Sci; 2008 Aug; 121(Pt 16):2731-43. PubMed ID: 18664490
[TBL] [Abstract][Full Text] [Related]
15. Three-dimensional organization of promyelocytic leukemia nuclear bodies.
Lang M; Jegou T; Chung I; Richter K; Münch S; Udvarhelyi A; Cremer C; Hemmerich P; Engelhardt J; Hell SW; Rippe K
J Cell Sci; 2010 Feb; 123(Pt 3):392-400. PubMed ID: 20130140
[TBL] [Abstract][Full Text] [Related]
16. The tumor suppressor SHIP1 colocalizes in nucleolar cavities with p53 and components of PML nuclear bodies.
Ehm P; Nalaskowski MM; Wundenberg T; Jücker M
Nucleus; 2015; 6(2):154-64. PubMed ID: 25723258
[TBL] [Abstract][Full Text] [Related]
17. Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.
Shishido-Hara Y; Higuchi K; Ohara S; Duyckaerts C; Hauw JJ; Uchihara T
J Neuropathol Exp Neurol; 2008 Apr; 67(4):299-308. PubMed ID: 18379438
[TBL] [Abstract][Full Text] [Related]
18. Involvement of PML nuclear bodies in CBP degradation through the ubiquitin-proteasome pathway.
St-Germain JR; Chen J; Li Q
Epigenetics; 2008 Nov; 3(6):342-9. PubMed ID: 19011377
[TBL] [Abstract][Full Text] [Related]
19. The ubiquitin-like modifier FAT10 interferes with SUMO activation.
Aichem A; Sailer C; Ryu S; Catone N; Stankovic-Valentin N; Schmidtke G; Melchior F; Stengel F; Groettrup M
Nat Commun; 2019 Oct; 10(1):4452. PubMed ID: 31575873
[TBL] [Abstract][Full Text] [Related]
20. Promyelocytic leukemia nuclear body-like structures can assemble in mouse oocytes.
Udagawa O; Kato-Udagawa A; Hirano S
Biol Open; 2022 Jun; 11(6):. PubMed ID: 35579421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
